– SYNB1020 currently being evaluated in a Phase 1b/2a clinical trial in patients with elevated ammonia due to cirrhosis; topline data expected by YE2018 – CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 4, 2018-- Synlogic , Inc. ( Nasdaq: SYBX ), a clinical-stage drug discovery and development company...

– Treated first subject in clinical trials of two Synthetic Biotic TM medicines, SYNB1020 and SYNB1618; both studies expected to generate data in 2018 – CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 15, 2018-- Synlogic, Inc. ( Nasdaq: SYBX ), a clinical stage company applying synthetic biology to

...

– Jose Carlos Gutiérrez- Ramos resigns as Synlogic’s President and Chief Executive Officer and member of its board of directors – – Aoife Brennan , current Synlogic Chief Medical Officer, named Interim President and Chief Executive Officer – CAMBRIDGE, Mass.

...

– Phase 1/2a clinical study of SYNB1618 evaluating safety and tolerability as well as exploratory endpoints expected to report interim data in 2018 – CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 25, 2018-- Synlogic ( Nasdaq: SYBX ), a clinical-stage company applying synthetic biology to probiotic

...

– Second Synthetic Biotic™ program to move into clinical studies in 2018 – – SAD/MAD study will include healthy volunteers and expansion cohorts of adult patients with PKU – – Interim data expected in 2018; full data in 2019 – CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr.

...

– Data highlight the application of Synthetic Biotic medicines for the potential treatment of a variety of solid tumors – – Company is advancing the first candidate from this program into IND-enabling studies in 2018 – CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr.

...

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 6, 2018-- Synlogic, Inc. (Nasdaq: SYBX) , a clinical-stage company applying synthetic biology to probiotics to develop novel living medicines, today announced that it has agreed to sell 3,280,000 shares of its common stock to a large mutual fund investor in

...

– First clinical trial of a Synthetic Biotic ™ Medicine in patients – – Randomized, double-blind, placebo-controlled study evaluating safety and tolerability of SYNB1020 as primary endpoint; ammonia-lowering as secondary endpoint – CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr.

...

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 21, 2018-- Synlogic (Nasdaq:SYBX) announced today that JC Gutiérrez-Ramos, Ph.D., Synlogic’s president and chief executive officer, will present a corporate update at the 17 th Annual Needham Healthcare Conference at 12:15 p.m....

– Strengthened balance sheet with $53.7M public offering; extended cash runway through 2019 – – Initiated Phase 1b/2a study evaluating SYNB1020 in patients with cirrhosis and hyperammonemia; topline data expected in 4Q 2018 – CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 20, 2018-- Synlogic, Inc....

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 19, 2018-- Synlogic, Inc. , (Nasdaq: SYBX ) a clinical-stage drug discovery and development company applying synthetic biology to probiotics to develop novel living medicines, today announced that preclinical data from its immuno-oncology (IO) program will...

– Expanded clinical data set from Phase 1 study confirms proof of mechanism and supports continued development of SYNB1020 for treatment of hyperammonemia – – A Phase 1b / 2a clinical trial to further evaluate SYNB1020 is open and screening patients – CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar....